Skip to main content
. 2025 Dec 8;26(24):11851. doi: 10.3390/ijms262411851
CI Confidence interval
HRD Homologous recombination deficiency
HRR Homologous recombination repair
LOH Loss of heterozygosity
mCRPC Metastatic castration-resistant prostate cancer
OR Odds ratio
PARPi Poly(ADP-ribose) polymerase inhibitors
PC Prostate cancer